Pfizer begins phase 3 study of mRNA based influenza vaccine
By, Admin1 min read
Share
Pfizer Inc. announced that the first participants have been dosed in a pivotal phase 3 clinical trial to evaluate the efficacy, safety, tolerability and immunogenicity of the company
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
